HRTX - Heron Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 1.42
52-Week Change 3-24.67%
S&P500 52-Week Change 313.08%
52 Week High 329.49
52 Week Low 315.68
50-Day Moving Average 319.42
200-Day Moving Average 318.52

Share Statistics

Avg Vol (3 month) 3993.08k
Avg Vol (10 day) 3994.21k
Shares Outstanding 588.39M
Float 77.87M
% Held by Insiders 10.13%
% Held by Institutions 1117.59%
Shares Short (Oct 31, 2019) 419.76M
Short Ratio (Oct 31, 2019) 416.03
Short % of Float (Oct 31, 2019) 434.78%
Short % of Shares Outstanding (Oct 31, 2019) 422.36%
Shares Short (prior month Sep 30, 2019) 418.71M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 220/1
Last Split Date 3Jan 13, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019


Profit Margin -140.55%
Operating Margin (ttm)-143.38%

Management Effectiveness

Return on Assets (ttm)-28.99%
Return on Equity (ttm)-56.74%

Income Statement

Revenue (ttm)139.73M
Revenue Per Share (ttm)1.77
Quarterly Revenue Growth (yoy)115.40%
Gross Profit (ttm)-88.27M
EBITDA -198.45M
Net Income Avi to Common (ttm)-196.39M
Diluted EPS (ttm)-2.48
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)256.28M
Total Cash Per Share (mrq)2.85
Total Debt (mrq)17.86M
Total Debt/Equity (mrq)6.26
Current Ratio (mrq)3.76
Book Value Per Share (mrq)3.57

Cash Flow Statement

Operating Cash Flow (ttm)-131.09M
Levered Free Cash Flow (ttm)-62.6M